Vistin Pharma Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Vistin Pharma.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Pharmaceuticals earnings growth	15.4%
Revenue growth rate	n/a
Future return on equity	n/a
Analyst coverage	None
Last updated	n/a

Recent future growth updates

Recent updates

Could The Vistin Pharma ASA (OB:VISTN) Ownership Structure Tell Us Something Useful?

Jan 29

The Vistin Pharma (OB:VISTN) Share Price Is Up 119% And Shareholders Are Boasting About It

Jan 08

Have Insiders Been Selling Vistin Pharma ASA (OB:VISTN) Shares?

Dec 16

Is Vistin Pharma ASA (OB:VISTIN) At Risk Of Cutting Its Dividend?

Nov 26

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Vistin Pharma has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

OB:VISTN - Analysts future estimates and past financials data (NOK Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
9/30/2024	427	61	56	100	N/A
6/30/2024	441	68	21	62	N/A
3/31/2024	441	56	35	74	N/A
12/31/2023	438	46	73	91	N/A
9/30/2023	439	45	39	77	N/A
6/30/2023	410	14	41	80	N/A
3/31/2023	373	7	-29	17	N/A
12/31/2022	305	-5	-75	-11	N/A
9/30/2022	272	-15	-90	-51	N/A
6/30/2022	243	-7	-97	-54	N/A
3/31/2022	241	1	-51	-5	N/A
12/31/2021	279	25	-18	14	N/A
9/30/2021	265	26	-19	42	N/A
6/30/2021	257	30	-24	47	N/A
3/31/2021	263	43	-186	-129	N/A
12/31/2020	254	-97	-199	-146	N/A
9/30/2020	246	-102	-174	-133	N/A
6/30/2020	259	-46	-147	-126	N/A
3/31/2020	247	-67	19	34	N/A
12/31/2019	228	66	1	19	N/A
9/30/2019	212	4	-14	-8	N/A
6/30/2019	196	-59	-32	-24	N/A
3/31/2019	190	-72	-60	-40	N/A
12/31/2018	201	-68	-58	-39	N/A
9/30/2018	200	-16	-33	-5	N/A
6/30/2018	194	-8	N/A	-22	N/A
3/31/2018	186	8	N/A	13	N/A
12/31/2017	175	5	N/A	10	N/A
9/30/2017	168	10	N/A	6	N/A
6/30/2017	160	7	N/A	41	N/A
3/31/2017	170	14	N/A	25	N/A
12/31/2016	173	16	N/A	54	N/A
9/30/2016	393	40	N/A	100	N/A
6/30/2016	446	46	N/A	60	N/A
12/31/2015	376	33	N/A	53	N/A
12/31/2014	361	-62	N/A	17	N/A
12/31/2013	347	8	N/A	21	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if VISTN's forecast earnings growth is above the savings rate (2.4%).

Earnings vs Market: Insufficient data to determine if VISTN's earnings are forecast to grow faster than the Norwegian market

High Growth Earnings: Insufficient data to determine if VISTN's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if VISTN's revenue is forecast to grow faster than the Norwegian market.

High Growth Revenue: Insufficient data to determine if VISTN's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if VISTN's Return on Equity is forecast to be high in 3 years time

Vistin Pharma Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Vistin Pharma ASA Provides Production Guidance for the Fourth Quarter and Year 2022

Recent updates

Third quarter 2024 earnings released: EPS: kr0.37 (vs kr0.53 in 3Q 2023)

Upcoming dividend of kr0.50 per share

Here's Why Vistin Pharma (OB:VISTN) Has Caught The Eye Of Investors

Now 21% undervalued

Second quarter 2024 earnings released: EPS: kr0.43 (vs kr0.16 in 2Q 2023)

Upcoming dividend of kr0.50 per share

Vistin Pharma ASA Approves Ordinary Dividend

First quarter 2024 earnings released: EPS: kr0.17 (vs kr0.067 loss in 1Q 2023)

Vistin Pharma ASA (OB:VISTN) acquired 15% stake in CF Pharma Ltd. for €1.6 million.

Full year 2023 earnings released: EPS: kr1.03 (vs kr0.11 loss in FY 2022)

Vistin Pharma ASA Proposes an Ordinary Dividend for the Accounting Year of 2023, Payable on or About 18 June 2024 and 19 November 2024

Upcoming dividend of kr0.75 per share at 3.1% yield

Vistin Pharma ASA Announces Cash Dividend, Payable on or About 30 January 2024

Vistin Pharma ASA Announces Cash Dividend, Payable on or About 30 January 2024

Vistin Pharma ASA, Annual General Meeting, May 23, 2024

Third quarter 2023 earnings released: EPS: kr0.53 (vs kr0.15 loss in 3Q 2022)

Vistin Pharma ASA Appoints Magnus Tolleshaug as the New CEO From, 1 January 2024

Second quarter 2023 earnings released: EPS: kr0.16 (vs kr0.005 in 2Q 2022)

Interim CEO recently bought kr360k worth of stock

First quarter 2023 earnings released: kr0.067 loss per share (vs kr0.34 loss in 1Q 2022)

Would Vistin Pharma (OB:VISTN) Be Better Off With Less Debt?

Full year 2022 earnings released: kr0.11 loss per share (vs kr0.56 profit in FY 2021)

Vistin Pharma ASA to Report Q3, 2023 Results on Oct 26, 2023

Less than half of directors are independent

Third quarter 2022 earnings released: kr0.15 loss per share (vs kr0.021 profit in 3Q 2021)

Vistin Pharma ASA Provides Production Guidance for the Fourth Quarter and Year 2022

Now 24% undervalued after recent price drop

Now 21% undervalued after recent price drop

A Look At The Fair Value Of Vistin Pharma ASA (OB:VISTN)

Second quarter 2022 earnings released: EPS: kr0.005 (vs kr0.18 in 2Q 2021)

Vistin Pharma ASA Approves Dividend for 2021

Less than half of directors are independent

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Vistin Pharma ASA Announces Executive Changes

Third quarter 2021 earnings released: EPS kr0.021 (vs kr0.10 in 3Q 2020)

Robust Earnings May Not Tell The Whole Story For Vistin Pharma (OB:VISTN)

Second quarter 2021 earnings released: EPS kr0.18 (vs kr0.47 in 2Q 2020)

Insider recently sold kr340k worth of stock

Upcoming dividend of kr0.50 per share

Vistin Pharma ASA Announces Dividend, Payable on 3 June 2021

First quarter 2021 earnings released

New 90-day high: kr27.00

Investors In Vistin Pharma ASA (OB:VISTN) Should Consider This, First

Full year 2020 earnings released: kr2.19 loss per share (vs kr1.49 profit in FY 2019)

We're Keeping An Eye On Vistin Pharma's (OB:VISTN) Cash Burn Rate

New 90-day high: kr21.70

Could The Vistin Pharma ASA (OB:VISTN) Ownership Structure Tell Us Something Useful?

The Vistin Pharma (OB:VISTN) Share Price Is Up 119% And Shareholders Are Boasting About It

New 90-day high: kr18.80

Have Insiders Been Selling Vistin Pharma ASA (OB:VISTN) Shares?

Is Vistin Pharma ASA (OB:VISTIN) At Risk Of Cutting Its Dividend?

Third quarter earnings released

First half earnings released

Chief Executive Officer recently sold kr1.6m worth of stock

New 90-day high - kr17.95

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies